Merck & Co., Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 5, 2024 and accepted by EDGAR at Aug 5, 2024, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $16.11bn | us-gaap:Revenues |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $31.89bn | us-gaap:Revenues |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $3.75bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $7.29bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $3.50bn | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $7.49bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-04-01 to 2024-06-30 | $2.74bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-01-01 to 2024-06-30 | $5.22bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $310.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $613.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $545.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-01-01 to 2024-06-30 | $1.45bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | $5.46bn | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | $10.22bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | $2.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | $4.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | $2.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | $4.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 2,544,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 2,544,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | $8.73bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $1.65bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2024-01-01 to 2024-06-30 | $3.94bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months2024-01-01 to 2024-06-30 | $373.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-06-30 | $11.30bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $38.20bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $112.63bn | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $26.06bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2024-06-30 | $34.72bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-06-30 | $3.07bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2024-06-30 | $43.58bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-034715. Last ingested by Listed: Oct 29, 2026, 06:44 ET. Listed shows no prices and gives no investment advice.